EGFR-IN-163

EGFR-IN-163 (Compound 13) is a competitive inhibitor of the epidermal growth factor receptor (EGFR) with an IC50 of 0.079 μM and selective inhibition on HER-2. It induces apoptosis in tumor cells and causes cell cycle arrest at the G2/M phase. EGFR-IN-163 shows promise for investigating estrogen receptor-positive (ER+) breast cancer.